SCHEMBL4187502

SCHEMBL4187502

COc1ccc(S(=O)(=O)N2C[C@@H]3C[C@H]2CN3S(=O)(=O)c2ccc(OC)c(OC)c2)cc1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.58
GPBAR1 Q8TDU6 1/20 0.56
MAPK1 P28482 3/20 0.53
TSHR P16473 3/20 0.53
POLB P06746 2/20 0.53
CTSG P08311 1/20 0.49
CMA1 P23946 1/20 0.49
USP2 O75604 1/20 0.48
LMNA P02545 1/20 0.48
GLA P06280 1/20 0.48
HSD17B10 Q99714 1/20 0.48
PDE4A P27815 1/20 0.48
PDE4B Q07343 1/20 0.48
PDE4C Q08493 1/20 0.48
PDE4D Q08499 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C19 P33261 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HCRTR1 O43613 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4184730 0.83 GPBAR1 (0.61) GPBAR1MAPK1TSHRPOLBUSP2
SCHEMBL4184732 0.83 GPBAR1 (0.61) GPBAR1MAPK1TSHRPOLBUSP2
SCHEMBL4182164 0.83 GPBAR1 (0.61) GPBAR1MAPK1TSHRPOLBUSP2
SCHEMBL13908425 0.80 GPBAR1 (0.61) GPBAR1MAPK1TSHRPOLBUSP2
SCHEMBL4184722 0.80 GPBAR1 (0.61) GPBAR1MAPK1TSHRPOLBUSP2
SCHEMBL4177318 0.79 GPBAR1 (0.54) GPBAR1MAPK1TSHRPOLBUSP2
SCHEMBL4609237 0.79 GPBAR1 (0.54) GPBAR1MAPK1TSHRPOLBUSP2
SCHEMBL3825843 0.78 HCRTR1 (0.53) GPBAR1MAPK1TSHRPOLBUSP2
SCHEMBL4186414 0.78 GPBAR1 (0.52) GPBAR1MAPK1TSHRPOLBUSP2
SCHEMBL1979123 0.78 ANPEP (0.53) GPBAR1POLBHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
US-20090069302-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2009-03-12 US disclosed
EP-1976498-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2008-10-08 EP disclosed
WO-2007127505-A2 USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM SMITHKLINE BEECHAM CORPORATION (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069302-A1 CHEMICAL COMPOUNDS TBXA2R, PDE4D, PDE4A HSD11B1 1576/4885GPBAR1 81/4885MAPK1 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.